U.S. Markets open in 6 hrs 53 mins

(BMY,CELG,PFE)


. Currency in USD
Add to watchlist
Full screen
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com11 hours ago

    [$$] Merck Cholesterol Drug Could Help Unlock Value

    In the last decade, no fewer than three major pharmaceutical companies have suffered defeat trying to bring a new class of cholesterol-lowering medication to market.s Much to the surprise of investors, Merck & Co. (MRK) could succeed where Pfizer (PFE), Roche (RHHBY) and Eli Lilly & Co. (LLY) have all failed. Merck has yet to decide if it will seek Food and Drug Administration approval, a sign to some that the company isn’t sure if the study data, though positive, are strong enough to ensure regulatory approval. Thanks to the growing success of Merck’s immunotherapy cancer drug Keytruda, the shares have gained 19% in the past year to near a 52-week high of $66.80.

  • Forbes15 hours ago

    A Closer Look At Bristol-Myers Squibb's Oncology Business

    Cancer drugs (oncology business) account for nearly 60% of Bristol-Myers Squibb's valuation, according to our estimates. Empirically and fundamentally speaking, the stock’s performance is highly tied to clinical trial results and the uptake of the company’s new cancer drugs.

  • Market Realist16 hours ago

    A Look at Pfizer’s Revenue for 1Q17

    Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.